PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
New England Journal of Medicine.
Times cited: 1805
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Journal of Hematology and Oncology.
Times cited: 36